Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Daiichi Sankyo Ltd ADR (OP: DSNKY ) 29.59 +0.25 (+0.87%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Daiichi Sankyo Ltd ADR < Previous 1 2 Next > Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients September 23, 2024 AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically significant improvement in overall survival. The trial met its progression-free... Via Benzinga Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study September 17, 2024 Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival... Via Benzinga AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial September 10, 2024 AstraZeneca shared detailed results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan for non-small cell lung cancer, showing a clinically meaningful trend in overall survival compared to... Via Benzinga DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q1 2024 August 13, 2024 Daiichi Sankyo Co just reported results for the first quarter of 2024. Via InvestorPlace Recession-Resilient Asian Stock Picks: TSMC, SK Hynix Among This Analyst's Top 10 August 07, 2024 "As stock pickers, we focus on a basket of stocks that we believe will emerge from the current drawdown," strategists say. Via Benzinga Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact March 20, 2023 Via Benzinga Daiichi Sankyo Seeks Approval In Japan For Its mRNA-Based COVID-19 Vaccine January 13, 2023 Via Benzinga Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast July 30, 2024 Merck reports Q2 sales of $16.1 billion, a 7% increase YoY, beating estimates. Keytruda sales surged 16% to $7.27 billion. FDA approvals for Capvaxive and Winrevair highlight the quarter. Merck revises... Via Benzinga Exposures Product Safety The 3 Most Undervalued Nasdaq 100 Stocks to Buy in July 2024 July 15, 2024 Undervalued Nasdaq 100 stocks may not be as rare as hen's teeth but not quite so plentiful amid a raging bull market. Via InvestorPlace FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug June 27, 2024 The FDA issued a Complete Response Letter for Daiichi Sankyo and Merck's BLA for patritumab deruxtecan targeting EGFR-mutated NSCLC due to third-party manufacturing facility inspection findings. The... Via Benzinga Exposures Product Safety Why Is AstraZeneca Stock Trading Lower On Tuesday? May 28, 2024 AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patients. While the overall trial did not reach statistical significance. Via Benzinga DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q3 2023 April 30, 2024 Daiichi Sankyo Co just reported results for the third quarter of 2023. Via InvestorPlace Double Good News For AstraZeneca's Breast Cancer Drugs April 29, 2024 Results from AstraZeneca's Enhertu trial vs. chemotherapy in HR-positive, HER2-low metastatic breast cancer. Via Benzinga AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor April 08, 2024 FDA approves Daiichi Sankyo's and AstraZeneca's Enhertu for unresectable or metastatic HER2+ solid tumors. Accelerated approval based on ORR and DOR. Boxed warnings for ILD/pneumonitis and embryo-fetal... Via Benzinga Exposures Product Safety What's Going On With Pfizer Stock Today? January 25, 2024 Pfizer to announce Q4 2023 earnings on 30th Jan. Analysts project EPS loss of $(0.22) and $14.25B in revenues. Via Benzinga Why Pharmaceutical Company Esperion Therapeutics Shares Are Diving Today January 03, 2024 Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares are trading lower on Wednesday after the company announced a $125 million amendment to the collaboration with Japanese pharma company Daiichi Sankyo... Via Benzinga Japan Emerges As Promising 2024 Investment Destination: 3 Stocks To Consider December 20, 2023 Japanese stocks are gaining favor among I-banks and sport attractive valuations; here are 3 stocks with low P/B that have outperformed and could generate shareholder wealth. Via Benzinga Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now? October 31, 2023 In due time, its new partnership with Daiichi Sankyo could be massive. Via The Motley Fool Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting September 22, 2023 AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSKYF) (OTC: Via Benzinga AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials September 11, 2023 Daiichi Sankyo (OTC: DSKYF) (OTC: DSNKY) and AstraZeneca plc (NASDAQ: AZN) released initial results from the TROPION-Lung04 phase 1b tria Via Benzinga FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt July 21, 2023 The FDA has approved Daiichi Sankyo's (OTC: DSNKY) Vanflyta (quizartinib) in Via Benzinga Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More July 04, 2023 World's Largest Psychedelics Conference Boasts 12K Attendees Via Benzinga AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial July 03, 2023 AstraZeneca Plc (NASDAQ: AZN) reported high-level results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) in patients with locally advanced or metastatic non-small cell lung... Via Benzinga Japanese Pharma Company Sponsors Australian Start Up In Development Of Non-Hallucinogenic Medicines June 27, 2023 Australia biotech startup Psylo has inked a sponsored research agreement with global Japanese pharmaceutical company Daiichi Sankyo (OTCMKTS: DSNKY) toward advancing antidepressant psychiatric... Via Benzinga AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting March 06, 2023 Via Benzinga Is Gilead Sciences a Good Stock to Buy Now? February 06, 2023 Gilead Sciences' breast cancer drug, Trodelvy, just took a big step forward. Via The Motley Fool AstraZeneca’s Next “Wonder Drug” January 19, 2023 Enhertu is an antibody-drug conjugate, a type of therapy designed to do minimal damage to healthy, non-cancerous cells. Wall Street analysts believe that Enhertu has the potential to become a key... Via Talk Markets AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs December 19, 2022 Via Benzinga AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients December 09, 2022 Via Benzinga European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs November 14, 2022 Via Benzinga < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
